158 related articles for article (PubMed ID: 31629395)
1. A Study for Therapeutic Treatment against Parkinson's Disease via Chou's 5-steps Rule.
Lan J; Liu Z; Liao C; Merkler DJ; Han Q; Li J
Curr Top Med Chem; 2019; 19(25):2318-2333. PubMed ID: 31629395
[TBL] [Abstract][Full Text] [Related]
2. Molecular characteristic and physiological role of DOPA-decarboxylase.
Guenter J; Lenartowski R
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1424-1440. PubMed ID: 28100850
[TBL] [Abstract][Full Text] [Related]
3. Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease.
Hadjiconstantinou M; Neff NH
CNS Neurosci Ther; 2008; 14(4):340-51. PubMed ID: 19040557
[TBL] [Abstract][Full Text] [Related]
4. Aromatic L-amino acid decarboxylase modulation and Parkinson's disease.
Neff NH; Hadjiconstantinou M
Prog Brain Res; 1995; 106():91-7. PubMed ID: 8584678
[TBL] [Abstract][Full Text] [Related]
5. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors.
Montioli R; Voltattorni CB; Bertoldi M
Curr Drug Metab; 2016; 17(5):513-8. PubMed ID: 27025882
[TBL] [Abstract][Full Text] [Related]
7. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease.
Leff SE; Spratt SK; Snyder RO; Mandel RJ
Neuroscience; 1999; 92(1):185-96. PubMed ID: 10392841
[TBL] [Abstract][Full Text] [Related]
8. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Boomsma F; van den Meiracker A; Man in 't Veld A; Schalekamp M
Life Sci; 1995; 57(19):1753-9. PubMed ID: 7475917
[TBL] [Abstract][Full Text] [Related]
9. Human L-Dopa decarboxylase interaction with annexin V and expression during apoptosis.
Chalatsa I; Arvanitis N; Arvanitis D; Tsakou AC; Kalantzis ED; Vassiliou AG; Sideris DC; Frakolaki E; Vassilaki N; Vassilacopoulou D
Biochimie; 2020 Oct; 177():78-86. PubMed ID: 32835737
[TBL] [Abstract][Full Text] [Related]
10. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
[TBL] [Abstract][Full Text] [Related]
12. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
13. Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
Ren LQ; Wienecke J; Hultborn H; Zhang M
J Neurotrauma; 2016 Jun; 33(12):1150-60. PubMed ID: 26830512
[TBL] [Abstract][Full Text] [Related]
14. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Wachtel SR; Bencsics C; Kang UJ
J Neurochem; 1997 Nov; 69(5):2055-63. PubMed ID: 9349551
[TBL] [Abstract][Full Text] [Related]
15. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Gil S; Park C; Lee J; Koh H
Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
[TBL] [Abstract][Full Text] [Related]
16. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
[TBL] [Abstract][Full Text] [Related]
17. Mammalian Dopa decarboxylase: structure, catalytic activity and inhibition.
Bertoldi M
Arch Biochem Biophys; 2014 Mar; 546():1-7. PubMed ID: 24407024
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease.
Hwu PW; Kiening K; Anselm I; Compton DR; Nakajima T; Opladen T; Pearl PL; Roubertie A; Roujeau T; Muramatsu SI
EMBO Mol Med; 2021 Sep; 13(9):e14712. PubMed ID: 34423905
[TBL] [Abstract][Full Text] [Related]
19. Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
Daidone F; Montioli R; Paiardini A; Cellini B; Macchiarulo A; Giardina G; Bossa F; Borri Voltattorni C
PLoS One; 2012; 7(2):e31610. PubMed ID: 22384042
[TBL] [Abstract][Full Text] [Related]
20. L-Dopa decarboxylase interaction with the major signaling regulator ΡΙ3Κ in tissues and cells of neural and peripheral origin.
Vassiliou AG; Siaterli MZ; Frakolaki E; Gkogkosi P; Paspaltsis I; Sklaviadis T; Vassilacopoulou D; Vassilaki N
Biochimie; 2019 May; 160():76-87. PubMed ID: 30796964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
